The Impact of AD Drug Treatments on Event-Related Potentials as Markers of Disease Conversion

Author(s): Robert M. Chapman, Anton P. Porsteinsson, Margaret N. Gardner, Mark Mapstone, John W. McCrary, Tiffany C. Sandoval, Maria D. Guillily, Lindsey A. Reilly, Elizabeth DeGrush

Journal Name: Current Alzheimer Research

Volume 10 , Issue 7 , 2013

Become EABM
Become Reviewer
Call for Editor


This paper investigates how commonly prescribed pharmacologic treatments for Alzheimer’s disease (AD) affect Event-Related Potential (ERP) biomarkers as tools for predicting AD conversion in individuals with Mild Cognitive Impairment (MCI). We gathered baseline ERP data from two MCI groups (those taking AD medications and those not) and later determined which subjects developed AD (Convert->AD) and which subjects remained cognitively stable (Stable). We utilized a previously developed and validated multivariate system of ERP components to measure medication effects among these four subgroups. Discriminant analysis produced classification scores for each individual as a measure of similarity to each clinical group (Convert->AD, Stable), and we found a large significant main Group effect but no main AD Medications effect and no Group by Medications interaction. This suggested AD medications have negligible influence on this set of ERP components as weighted markers of disease progression. These results provide practical information to those using ERP measures as a biomarker to identify and track AD in individuals in a clinical or research setting.

Keywords: Alzheimer’ s disease (AD), AD drug treatments, biomarker, discriminant analysis, EEG, event-related potentials (ERP), mild cognitive impairment (MCI), neurophysiology, prediction, principal components analysis (PCA).

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2013
Published on: 20 August, 2013
Page: [732 - 741]
Pages: 10
DOI: 10.2174/15672050113109990148
Price: $65

Article Metrics

PDF: 7